An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1

NCT03259633 · clinicaltrials.gov ↗

APPROVED_FOR_MARKETING

Status

INDUSTRY

Sponsor class

Conditions

NF type1 With Inoperable Plexiform Neurofibromas

Interventions

DRUG: Selumetinib

Sponsor

AstraZeneca